Sky Labs' CART BP Pro Ring Heads to Europe After 260K+ South Korean Prescriptions

Cuffless continuous blood pressure monitoring in a ring form factor has been a hardware promise for years. Sky Labs is making a clinical credibility argument that most competitors can’t yet match.

What Happened

Sky Labs presented data for its CART BP pro ring at two major cardiology conferences in June 2026: the 35th European Society of Hypertension Congress and the British Cardiovascular Society Annual Conference. The company announced that the device is now cleared for launch in Europe (CE-MDR certification received January 2026) and the United Kingdom (UK MHRA registered), and that it has accumulated over 260,000 prescriptions in South Korea as of May 2026.

According to Longevity Technology’s coverage, the company reports the device meets ISO 81060-2:2018 accuracy standards for blood pressure monitors and has passed European Society of Hypertension cuffless device validation protocols.

Why It Matters

The prescription count matters because it distinguishes CART BP pro from the category of consumer wellness gadgets that self-report blood pressure estimates without regulatory oversight. 260,000+ prescriptions in South Korea means Korean clinicians have been issuing this device as a medical-grade tool in clinical pathways — not just direct-to-consumer sales. That’s a meaningful proof-of-use before the European regulatory expansion.

The ISO 81060-2:2018 compliance claim is the accuracy standard that blood pressure device manufacturers are expected to meet for clinical use. Cuffless devices have historically struggled to pass this validation — many consumer devices (including features on popular smartwatches) operate in regulatory gray zones that don’t require this standard. Sky Labs presenting data at ESH and BCS — the leading European cardiology conferences — signals it’s pursuing clinical rather than consumer market positioning.

Implications

For hypertension management, a ring-form cuffless monitor that meets clinical accuracy standards changes what’s possible in ambulatory blood pressure monitoring. Traditional ambulatory monitoring uses an upper-arm cuff that inflates every 15–30 minutes during a 24-hour period — effective but disruptive. A ring that measures continuously without inflation enables a different class of data, including nocturnal dipping patterns and beat-to-beat variability that cuff devices miss between measurements.

The European rollout timing follows a pattern of South Korean regulatory frameworks serving as a proving ground for medical devices before Western market entry. The broader smart ring category has been moving in this direction, but cardiovascular monitoring at this regulatory level is a higher bar than sleep or activity tracking.

Prescription model vs. direct-to-consumer sale is the key market variable. If CART BP pro enters Europe primarily through prescription channels rather than retail, adoption will be slower but the clinical relationship is stronger — physicians manage BP data interpretation, which matters for a device measuring a safety-critical vital sign.

Content created with AI assistance and reviewed for accuracy.